Scribe Therapeutics to Present Updated PCSK9 and LPA Program Data
Scribe Therapeutics plans to present updated data on its PCSK9-targeting epigenetic silencing and LPA-targeting gene editing programs at the 2026 AHA Scientific Sessions.
Scribe Therapeutics plans to present updated data on its PCSK9-targeting epigenetic silencing and LPA-targeting gene editing programs at the 2026 AHA Scientific Sessions.